InvestorsHub Logo
Followers 112
Posts 8468
Boards Moderated 0
Alias Born 02/27/2016

Re: None

Thursday, 01/21/2021 5:04:52 PM

Thursday, January 21, 2021 5:04:52 PM

Post# of 44690
WOULD ADVITABE BE BOUGHT IF RLFTF MANAGEMENT WAS NOT SURE AVIPTADIL WORKED?





rollup Thursday, 01/21/21 01:56:29 PM
Re: None 0
Post #
34024
of 34031
Relief Therapeutics buys German Advita

01/21/2021
from tt

Relief Therapeutics plans to take over the life science company for EUR 25 million and invest up to EUR 20 million.


Relief Therapeutics Holding AG in Geneva plans to buy Advita Lifescience GmbH in Denzlingen near Freiburg for EUR 25 million, and the company has announced a letter of intent. They also agreed on success-related milestone payments of up to EUR 20 million. The goal is to develop a COVID-19 therapeutic agent.

Relief will acquire all shares in Advita. In return, Advita Relief will receive ordinary shares worth EUR 25 million as well as the milestone payments. The transaction is expected to close in the second quarter of 2021.

Relief is a biopharmaceutical company whose lead drug candidate RLF-100 (Aviptadil) is in advanced clinical development for the treatment of patients with severe COVID-19 disease. Among other things, Advita develops products to improve the treatment and diagnosis of rare lung diseases. In addition to the Advita assets, Relief claims that it will receive further pending patent rights covering the specifications for inhaled RLF-100 formulations and the possible use of Aviptadil as inhalative therapy for acute respiratory distress syndrome (ARDS) and checkpoint inhibitor cover induced pneumonitis.

"Advita's intellectual property with respect to inhaled formulations of Aviptadil and the company's expertise with respect to this active ingredient will be used in the development of the inhaled formulation of RLF-100 for the treatment of COVID-19-related ARDS and other potential indications in the area of Lung diseases such as pulmonary sarcoid and chronic berylliasis will be invaluable, "said Jack Weinstein, chief financial officer of Relief.

© transkript.de


InvestorsHub NewsWire
Featured $5.2M MKT CAP AIRTEST PRODUCTS WITH MAJOR COMPETITIVE ADVANTAGES IN $35B INDOOR AIR QUALITY MARKET COULD EXPLODE SALES Jan 21, 2021 8:30 AM

ALYI Sees President Biden Rejoining Paris Climate Accord As Boost To Electric Vehicle Market • ALYI • Jan 21, 2021 3:08 PM

IQST - iQSTEL Inc.'s Market Cap Is Overlooking Two Important Things - Its Record Revenues And Seven Subsidiary Companies • IQST • Jan 21, 2021 1:46 PM

WSGF - Vaycaychella Backed Boutique Hotel Opening Soon In $32 Billion Caribbean Vacation Market • WSGF • Jan 21, 2021 10:48 AM

NxGen Brands, Inc. Acquires Exclusive License To Utilize & Market Various High Demand Technologies • NXGB • Jan 21, 2021 10:33 AM

PENNEXX Prepares for Uplisting to OTCQB, Discusses the Value of its $34.9 Million NOL Carryforward • PNNX • Jan 21, 2021 10:23 AM

Gaensel Completes Acquisition of 65% of Renewable Energy Powerhouse Simeti Group Limited and Implementation of its One Hundre... • GEGR • Jan 21, 2021 10:20 AM

American Cannabis Announces LOI for Acquisition of a 60,000-sq. ft. Cannabis Cultivation and Extraction Operation in Denver... • AMMJ • Jan 21, 2021 9:53 AM

SILVER TIGER MAKES NEW DISCOVERY OF THE BENJAMIN VEIN • SLVR • Jan 21, 2021 9:42 AM